Indication

For the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.

Medicine details

Medicine name:
mogamulizumab (Poteligeo)
SMC ID:
SMC2336
Pharmaceutical company
Kyowa Kirin
Submission type
Full
Publication due date:
Q2 2021
SMC meeting date:
Q2 2021
Patient group submission deadline:
01 March 2021